Our approach here was to determine if FOXM1 has a role in 5-FU resistance and if FOXM1 controls the expression of TYMS, a crucial target of anti-pyrimidines, commonly used to treat CRC. The gene discussed is TYMS; the disease is colorectal carcinoma.